Chicago, Sept. 14, 2003 – A treatment regimen of Ziagen® (abacavir sulfate) (ABC), Epivir® (lamivudine) (3TC) and efavirenz (EFV) has been shown to be non-inferior to the often prescribed regimen of Retrovir® (zidovudine) (ZDV) and 3TC and EFV in a large Phase III clinical trial comparing virologic response in treatment-naïve HIV+ adults. The 48-week data from the trial (CNA30024) were reported here today at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Study CNA30024 enrolled therapy-naïve adults and randomized them to treatment with (1) ABC 300mg twice daily plus 3TC 150mg twice daily plus EFV 600mg once daily...